| Aptose Biosciences is biotechnology company developing agents to treat medical needs in cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Co.'s product pipeline includes cancer drug candidates that exert potent activity as stand-alone agents and that improve the activities of other anticancer agents without causing overlapping toxicities. Co.'s clinical-stage programs include: CG-806, which is a mutation-agnostic FMS-like tyrosine kinase 3 / Bruton's tyrosine kinase inhibitor; and APTO-253, which is a small molecule MYC oncogene inhibitor. We show 16 historical shares outstanding datapoints in our APTO shares outstanding history coverage, used to compute APTO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APTO market cap history over the course of time is important for investors
interested in comparing APTO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APTO versus a peer is one thing; comparing
APTO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APTO can fluctuate over the course of history.
With this page we aim to empower investors researching APTO by allowing them to research the APTO market cap history.